Login
Companies $CTMX
$2.02 +$0.03 (1.76%) After hours
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc.

cytomx.com

What Do They Do?

Develops masked biologic cancer drug candidates for patients with colorectal cancer, melanoma and other solid tumors.

How Do They Make Money?

FY2025 revenue

Who Are Their Customers?

Works with biopharmaceutical companies through strategic research alliances; revenue is reported from Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna.

Do Revenues Turn Into Profits?

No. It lost $17.4M in FY2025.

Operating income, FY2025
−29% of revenue
▼ Turned to a loss vs FY2024 ($25M, 18%)
Net income, FY2025
−23% of revenue
▼ Turned to a loss vs FY2024 ($31.9M, 23%)
Free cash flow, FY2025
−99% of revenue
▲ +12% (Loss) vs FY2024 (−$86.5M, −63%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −72%
vs $6M in Q3 FY2025
Net income
▼ −41% (Loss)
vs −$14.2M in Q3 FY2025
  • Jun 3, 2026 Regeneron expanded its collaboration to include additional programs Regeneron nominated two programs, entitling CytomX to $37.0 million in target nomination payments.

Growing. Revenue grew 2.0x in 4 years, from $37.3M in FY2021 to $76.2M in FY2025, about 20% a year.

Candidates advance to clinical testing The older report placed an EpCAM-targeting antibody-drug conjugate and a masked interferon candidate in preclinical development; the latest report describes those programs as clinical-stage.

Who Do They Compete With?

Competes with AbbVie, Adagene, Amgen, BioAtla, Halozyme Therapeutics, Merck, Roche, Sanofi, Takeda Pharmaceutical, Werewolf Therapeutics, Janux Therapeutics, Xilio Therapeutics, Vir Biotechnology, Daiichi Sankyo, Gilead Sciences, Pfizer, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, and Novartis

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support